Education
About Us
Working with TipRanks
Follow Us
CytomX Therapeutics Inc (CTMX)
NASDAQ:CTMX
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.06Last Year’s EPS
0.17Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 06, 2025
|% Change Since: -14.52%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in advancing clinical programs and strong financial performance, especially through strategic partnerships and increased revenue. However, challenges include the discontinuation of CX-904 and a decrease in cash reserves. Overall, the positive aspects slightly outweigh the negatives.Company Guidance
In the fourth quarter of 2024 financial results call, CytomX Therapeutics provided detailed guidance on their pipeline progress and financial outlook. They highlighted the advancement of two new clinical programs, CX-2051 and CX-801, prioritizing these to optimize resource allocation and extending their cash runway to the second quarter of 2026. They aim to generate initial clinical data for both programs in 2025, with CX-2051 targeting colorectal cancer as a first-in-class ADC and CX-801 as a next-generation targeted immunotherapy. Financially, the company reported $138.1 million in revenue for 2024, an increase from $101.2 million in 2023, and ended the year with $100.6 million in cash, cash equivalents, and investments, compared to $174.5 million in 2023. The increase in revenue was attributed to collaborations with companies like Bristol Myers Squibb and Moderna. Total operating expenses for 2024 were $113.1 million, slightly up from $107.7 million in 2023, primarily due to a milestone payment to AbbVie.Advancement of Clinical Programs
In 2024, CytomX advanced two new programs, CX-2051 and CX-801, into the clinic, prioritizing these programs and streamlining the organization to extend the cash runway to Q2 2026.
Financial Performance
Total revenue for 2024 was $138.1 million, up from $101.2 million in 2023, attributed to collaborations with BMS, Moderna, Astellas, and Regeneron.
Pipeline Progress and Strategic Partnerships
CytomX achieved a $5 million milestone payment from Astellas and continues progress with partnerships involving Bristol Myers Squibb, Amgen, Moderna, and Regeneron.
---
CTMX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CTMX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 06, 2025 | $0.62 | $0.66 | +6.45% |
| Nov 07, 2024 | $1.00 | $1.09 | +9.00% |
| Aug 08, 2024 | $1.18 | $1.20 | +1.69% |
| May 08, 2024 | $4.19 | $2.04 | -51.31% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does CytomX Therapeutics Inc (CTMX) report earnings?
CytomX Therapeutics Inc (CTMX) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is CytomX Therapeutics Inc (CTMX) earnings time?
CytomX Therapeutics Inc (CTMX) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CTMX EPS forecast?
CTMX EPS forecast for the fiscal quarter 2025 (Q1) is 0.06.
---